CervoMed Inc. (CRVO) is a Healthcare stock trading at $2.62 (as of 2026-08-21), with a market capitalization of $39.61M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
CervoMed Inc. is a clinical-stage biotechnology company developing and commercializing drug treatments for neurodegenerative conditions. Its program centers on neflamapimod, an orally administered small-molecule intended for brain-penetrant therapy in dementia with Lewy bodies, Alzheimer’s disease, and brain stroke recovery.
CervoMed Inc. develops drug treatments for neurodegenerative diseases, including neflamapimod, an orally administered small molecule designed to penetrate the brain, and it aims to commercialize those therapies.
In the current stage reflected by the latest quarter, CervoMed appears to generate no product revenue, so profitability largely depends on clinical progress and the ability to fund development (including grant revenue), while commercialization timing remains uncertain.
| Grant Revenue | $0.0B |
Business quality (Weak): Clinical-stage biotech with 0 revenue in the latest reported quarter and a very large operating loss, with progress tracked through clinical endpoints (for example, Week 32 risk reduction) and trial execution metrics.
| Price | $2.62 |
| Market Cap | $39.61M |
| Price / Book | 1.73 |
| Price / Sales | 119.57 |
| Revenue (TTM) | $4.01M |
| Net Margin | -673.1% |
| Revenue Growth (YoY) | -100.0% |
| EPS Growth (YoY) | -8.6% |
| Altman Z-Score | -5.80 (distress) |
| Sector P/E (Healthcare) | 21.7 |
| Industry P/E (Pharmaceutical Products) | 17.0 |
| Top Institutional Holder | AWM Investment Company, Inc. ($6.28M) |
| Institutional Holders Tracked | 10 |
| Sector | Healthcare |
| Industry | Pharmaceutical Products |
| CEO | John J. Alam |
| Employees | 15 |
| Country | US |
| IPO Date | 2008-05-23 |
Data as of 2026-08-21.
Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.